MMP9 and neoplasm: Cotreatment with anti–MMP-9 and anti-PDL1 antibodies increased the proportion of CD3+ cells among tumor-infiltrating leukocytes (Fig 4B), consistent with the observed increase in TCR diversity (Fig 3C).